|
May 9
|
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
|
|
May 9
|
Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
|
|
May 9
|
Aquestive Therapeutics Inc (AQST) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
|
|
May 7
|
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
|
|
May 7
|
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 7
|
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 6
|
Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?
|
|
May 2
|
Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
|
|
Apr 30
|
Analysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for
|
|
Apr 29
|
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
|
|
Apr 25
|
Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
|
|
Apr 17
|
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
|
|
Apr 12
|
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
|
|
Apr 2
|
Aquestive Therapeutics (AQST) Ascends While Market Falls: Some Facts to Note
|
|
Apr 1
|
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
|
|
Mar 25
|
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
|
|
Mar 22
|
Aquestive Therapeutics (AQST) Flat As Market Sinks: What You Should Know
|
|
Mar 20
|
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
|
|
Mar 19
|
Insider Sell: Chief Innovation/Tech Officer Alexander Schobel Sells 50,000 Shares of Aquestive ...
|